Medasense Founder and CEO Galit Zuckerman-Stark has been named one of 13 finalists for the EU Prize for Women Innovators 2020.
Treating Pain is at the
Heart of Medicine
Medasense is the developer of a unique technology that objectively monitors and quantifies the patient’s pain response level using artificial intelligence algorithms and a proprietary noninvasive sensor platform.
NOL technology is used to optimize pain management in critical care settings, where anaesthetized patients are unable to communicate.
Interface connectivity is enabled with Philips patient monitors, enabling a consolidated view of changes in pain response level alongside vital signs.
The technology is distributed across Europe exclusively by Medtronic, and by leading partners in other regions.
DISTRIBUTION MAP
nol technology
Eliminate guesswork and meet clinical challenges in assessing pain and optimizing analgesia.
CLINICAL EVIDENCE
Recent clinical studies have demonstrated the impact that NOL monitoring has on patient safety and outcomes, including reduced intraoperative opioid consumption.1
MEDASENSE ACADEMY
Welcome to our online and customized education and training program for clinicians and commercial partners.
The essence of Medasense: Guiding critical care clinicians for optimal pain care
Meeting the challenge of intraoperative pain monitoring
Leading clinicians on the importance of monitoring the patient’s pain response level
Clinical Collaborations
REFERENCES:
1. Meijer, F., Martini, C., Broens, S., Boon, M., Niesters, M., Aarts, L., Olofsen, E., van Velzen, M., Dahan, A. (2019). Nociception-guided versus Standard Care during Remifentanil–Propofol Anesthesia: A Randomized Controlled Trial. Anesthesiology, 130(5), 745-755. doi:10.1097/ALN.0000000000002634